v3.24.2.u1
Segment Reporting (Details) - Schedule of Our Chief Officer Decision Maker Evaluates Segment Performance - USD ($)
 3 Months Ended 6 Months Ended
Jul. 31, 2024
Jul. 31, 2023
Jul. 31, 2024
Jul. 31, 2023
Schedule of Our Chief Officer Decision Maker Evaluates Segment Performance [Line Items]        
Net sales $ 442,830 $ 655,928 $ 851,362 $ 1,132,860
Gross profit 101,558 299,672 266,344 521,957
Operating expenses 1,511,300 1,123,860 3,565,563 2,364,022
Depreciation and Amortization 69,949 76,010 139,050 150,511
Pocono Pharmaceuticals [Member]        
Schedule of Our Chief Officer Decision Maker Evaluates Segment Performance [Line Items]        
Net sales 442,830 566,769 851,362 967,826
Gross profit 101,558 236,731 266,344 400,061
Operating expenses 166,674 135,420 321,068 272,283
Depreciation and Amortization 57,671 56,017 114,494 111,225
4P Therapeutics [Member]        
Schedule of Our Chief Officer Decision Maker Evaluates Segment Performance [Line Items]        
Net sales 89,159 165,034
Gross profit 62,941 121,896
Operating expenses 30,249 45,466 54,603 62,837
Depreciation and Amortization 9,268 16,496 18,535 32,292
Corporate [Member]        
Schedule of Our Chief Officer Decision Maker Evaluates Segment Performance [Line Items]        
Operating expenses 540,402 497,852 1,441,382 1,183,350
Depreciation and Amortization 3,010 3,497 6,021 6,994
Research and development-4P Therapeutics [Member]        
Schedule of Our Chief Officer Decision Maker Evaluates Segment Performance [Line Items]        
Operating expenses $ 773,975 $ 445,122 $ 1,748,510 $ 845,552